Hikal (524735) Panoramica del titolo
Hikal Limited, insieme alle sue consociate, produce e vende vari intermedi chimici, specialità chimiche e ingredienti farmaceutici attivi a società farmaceutiche, di salute animale, biotecnologiche, di protezione delle colture e di specialità chimiche in India, Stati Uniti, Canada, Europa, Sud-Est asiatico e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 1/6 |
524735 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Hikal Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹228.85 |
| Massimo di 52 settimane | ₹355.00 |
| Minimo di 52 settimane | ₹145.95 |
| Beta | 0.56 |
| Variazione di 1 mese | 27.39% |
| Variazione a 3 mesi | 30.85% |
| Variazione di 1 anno | -33.26% |
| Variazione a 3 anni | -25.21% |
| Variazione a 5 anni | -55.87% |
| Variazione dall'IPO | 22,287.57% |
Notizie e aggiornamenti recenti
524735: Dividend And Board Changes Will Support Future Upside Potential
Analysts have trimmed their price target for Hikal from ₹320 to ₹300, reflecting updated assumptions for slightly lower revenue growth, a softer profit margin outlook, and a higher future P/E multiple. What’s in the News for Hikal Hikal has scheduled a Special or Extraordinary Shareholders Meeting on July 4, 2026, to be conducted via postal ballot in India.524735: Board Actions And Dividend Decision Will Support Future Upside Potential
Analysts have kept Hikal's fair value unchanged at ₹320.0 while adjusting underlying assumptions, including a slightly higher discount rate, revised revenue growth and profit margin inputs, and a lower future P/E, which together shape the refreshed price target narrative. What's in the News A board meeting is scheduled for May 27, 2026, at 11:00 IST to review and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.524735: Interim Dividend And Stable Assumptions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320, reflecting unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend on equity shares for FY 2025-26 (company filing).Recent updates
524735: Dividend And Board Changes Will Support Future Upside Potential
Analysts have trimmed their price target for Hikal from ₹320 to ₹300, reflecting updated assumptions for slightly lower revenue growth, a softer profit margin outlook, and a higher future P/E multiple. What’s in the News for Hikal Hikal has scheduled a Special or Extraordinary Shareholders Meeting on July 4, 2026, to be conducted via postal ballot in India.524735: Board Actions And Dividend Decision Will Support Future Upside Potential
Analysts have kept Hikal's fair value unchanged at ₹320.0 while adjusting underlying assumptions, including a slightly higher discount rate, revised revenue growth and profit margin inputs, and a lower future P/E, which together shape the refreshed price target narrative. What's in the News A board meeting is scheduled for May 27, 2026, at 11:00 IST to review and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.524735: Interim Dividend And Stable Assumptions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320, reflecting unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend on equity shares for FY 2025-26 (company filing).524735: Interim Dividend And Steady Assumptions Will Support Bullish Upside Potential
Analysts have maintained their fair value estimate for Hikal at ₹320, citing essentially unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E. This keeps their overall price target view steady.524735: Interim Dividend And Stable Assumptions Will Support Bullish Upside Potential
Analysts have kept their fair value estimate for Hikal broadly unchanged at around ₹320, reflecting largely steady assumptions on discount rate, revenue growth, profit margin and future P/E, and signaling no meaningful shift in their overall view of the stock. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).524735: Interim Dividend And Stable Outlook Will Support Bullish Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320. This points to largely unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiple in their latest price target update.524735: Interim Dividend And Upcoming Results Will Support Bullish Upside Potential
Analysts have kept their price target on Hikal unchanged at ₹320, reflecting broadly steady views on revenue growth, margins and fair value, with only a small adjustment to the assumed future P/E multiple. What's in the News The Board will meet on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend for FY 2025-26 (company filing).524735: Upcoming Results And Interim Dividend Decision Will Support Future Upside
Analysts have lifted their price target on Hikal to ₹320, reflecting updated assumptions around a lower discount rate, faster revenue growth, a slimmer profit margin, and a higher future P/E multiple. What's in the News Board meeting scheduled on Feb 11, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).524735: Stable Margins And Upcoming Results Will Support Future Dividend Upside
Analysts have kept their fair value estimate for Hikal steady at ₹320.0 per share. This reflects unchanged views on growth, margins, discount rate, and future P/E assumptions used in their price target work.524735: Profitability Will Improve As Stable Margins Support Future Dividend Upside
Analysts have modestly reiterated their outlook on Hikal, keeping the average 12 month price target broadly stable around ₹320 per share, as unchanged growth, margin, and valuation assumptions continue to support a steady fair value profile. What's in the News Board meeting scheduled for November 13, 2025, to review and approve standalone and consolidated unaudited financial results for Q2 and H1 FY2025 (company filing) Shareholders at the 37th AGM on September 23, 2025, approved a final dividend of INR 0.80 per equity share of INR 2, taking the total FY2024-25 dividend to INR 1.40 per share (AGM resolution) Valuation Changes Fair Value: Unchanged at approximately ₹320 per share, indicating a stable assessment of intrinsic value.524735: Profitability Will Improve As Margins Recover And Regulatory Risks Fade
Analysts have raised their price target for Hikal to ₹320.00, citing improved forecasts for revenue growth and profit margin in addition to a stronger outlook for future profitability. What's in the News A board meeting is scheduled for November 13, 2025, to approve unaudited financial results for the second quarter and half year ended September 30, 2025 (Key Developments).524735: Future Margins Will Recover Following Regulatory Facility Improvements
Narrative Update: Hikal Analyst Price Target Adjustment Analysts have decreased their fair value estimate for Hikal from ₹390 to ₹320 due to revised expectations for revenue decline and lower profit margins. What's in the News The United States FDA issued a warning letter to Hikal's drug manufacturing facility in Karnataka following an inspection in February 2025.Global Supply Chain Diversification Will Unlock Indian CRAMS Potential
As both net profit margin and consensus revenue growth forecasts for Hikal remained stable, analysts have maintained their fair value estimate with the price target unchanged at ₹390.00. What's in the News Hikal's Board of Directors will meet to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2025.
New Panoli Facility And Global Expansions Will Strengthen Operations Over Next 2-3 Years
Strategic focus on operating leverage and product mix is set to improve net margins and revenue diversification.Rendimenti per gli azionisti
| 524735 | IN Pharmaceuticals | IN Mercato | |
|---|---|---|---|
| 7D | 4.6% | 1.3% | 1.2% |
| 1Y | -33.3% | 13.9% | -1.3% |
Ritorno vs Industria: 524735 ha avuto una performance inferiore rispetto al Indian Pharmaceuticals che ha registrato un rendimento 13.9 % nell'ultimo anno.
Rendimento vs Mercato: 524735 ha avuto una performance inferiore al mercato Indian che ha registrato un rendimento -1.3 % nell'ultimo anno.
Volatilità dei prezzi
| 524735 volatility | |
|---|---|
| 524735 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 4.0% |
Prezzo delle azioni stabile: 524735 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di 524735 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1988 | 2,062 | Sameer Hiremath | www.hikal.com |
Hikal Limited, insieme alle sue consociate, produce e vende vari intermedi chimici, specialità chimiche e principi attivi farmaceutici a società farmaceutiche, di salute animale, biotecnologiche, di protezione delle colture e di specialità chimiche in India, Stati Uniti, Canada, Europa, Sud-Est asiatico e a livello internazionale. L'azienda opera attraverso due segmenti, Pharmaceuticals e Crop Protection. Il segmento Pharmaceuticals produce ingredienti farmaceutici attivi (API).
Hikal Limited Riepilogo dei fondamenti
| 524735 statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹26.85b |
| Utili (TTM) | -₹488.00m |
| Ricavi(TTM) | ₹17.13b |
524735 è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| 524735 Conto economico (TTM) | |
|---|---|
| Ricavi | ₹17.13b |
| Costo del fatturato | ₹7.62b |
| Profitto lordo | ₹9.51b |
| Altre spese | ₹10.00b |
| Utili | -₹488.00m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -3.96 |
| Margine lordo | 55.52% |
| Margine di profitto netto | -2.85% |
| Rapporto debito/patrimonio netto | 56.8% |
Come si è comportato 524735 nel lungo periodo?
Vedi performance storica e confrontoDividendi
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/08 12:19 |
| Prezzo dell'azione a fine giornata | 2026/07/08 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Hikal Limited è coperta da 2 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Kameswari V. S. Chavali | FirstCall Research |